Gregory D. Perry - 15 Jun 2025 Form 4 Insider Report for KALA BIO, Inc. (KALA)

Reporting relationship: Director
Issuer ticker: KALA
Reported as of: 15 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2025, 20:00:10 UTC
Prior SEC filing: 31 Jan 2025
Next SEC filing: 12 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Mary Reumuth, Attorney-in-Fact

Key filing fact

Gregory D. Perry filed Form 4 for KALA BIO, Inc. (KALA) on 17 Jun 2025.

Key facts

This page summarizes Gregory D. Perry's Form 4 filing for KALA BIO, Inc. (KALA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2025, 20:00.

Change

Previous filing in this sequence was filed on 31 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001236371 Primary reporting owner

PERRY GREGORY D

Relationship: Director
Address: C/O KALA BIO, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON
Signature: /s/ Mary Reumuth, Attorney-in-Fact
Signature date: 17 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KALA transaction

Common Stock

Award

Transaction value: $0
Shares: +2,450
Change %: +22%
Price: $0.000000
Shares after: 13,344
Date: 15 Jun 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KALA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +5,450
Change %
Price: $0.000000
Shares after: 5,450
Date: 15 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,450
Exercise price: $4.30
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.

Footnote F2

Includes 6,355 unvested RSUs.

Footnote F3

This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.